Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PRM-151

Known as: PRM-151/PTX2, Recombinant Human PTX2, Recombinant Human Serum Amyloid P/Pentraxin 2 
A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Homeodomain ProteinsRecombinant ProteinsSerum Amyloid P-Component

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
BACKGROUND Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a recombinant human pentraxin 2 protein, in a… Expand
2018
2018
PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
Introduction: PRM-151, a recombinant human pentraxin-2 molecule, has been shown to prevent and reverse fibrosis in animal models… Expand
2016
2016
Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.
Pentraxin-2 (PTX-2), also known as serum amyloid P component (SAP/APCS), is a constitutive, antiinflammatory, innate immune… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy
Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic… Expand
2014
2014
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results
PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue damage, inducing… Expand
2014
2014
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
7114 Background: PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue… Expand
Highly Cited
2013
Highly Cited
2013
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.
PRM-151, recombinant human Pentraxin-2 (PTX-2) also referred to as serum amyloid P (SAP), is under development for treatment of… Expand
  • figure 1
  • table 1
  • figure 2
2013
2013
Characterization and stabilization of recombinant human protein pentraxin (rhPTX-2).
The potential human therapeutic protein pentraxin (PTX-2) is a large, glycosylated plasma protein consisting of five monomers… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2011
2011
Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits.
This study investigated whether PRM-151 (Promedior, Inc., Malvern, PA), a recombinant form of human pentraxin-2 (PTX-2, also… Expand
  • figure 1
Review
2010
Review
2010
PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis.
Serum amyloid P or pentraxin 2 (PTX2) is a highly phylogenetically conserved, naturally circulating plasma protein and a soluble… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE